If future trials confirm this signal, drugs like petrelintide could offer an interesting alternative for patients who struggle with gastrointestinal side effects from incretin-based therapies
Mechanism of Action Comparison# Retatrutide# Retatrutide (LY3437943) is a 39-amino acid peptide that simultaneously activates three metabolically important receptors: GLP-1 receptor : Enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes central satiety signaling GIP receptor : Potentiates insulin secretion, may improve beta-cell function, and contributes to adipose tissue metabolism Glucagon receptor : Increases hepatic glucose output acutely but chronically promotes hepatic fat oxidation, thermogenesis, and energy expenditure The glucagon receptor component distinguishes retatrutide from all other approved or late-stage metabolic peptides
Those reasons indicate which symptoms already exist and which may appear after treatment begins
Study author Steven Luo, from the School of Clinical Medicine and Trinity College, said: When stopping weight-loss drugs, doctors and patients should be aware of the potential for weight regain and consider ways to mitigate this risk
For the majority, this side effect grows more tolerable as time passes, particularly when the dose is titrated up gradually as in clinical trials